Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Cesca Therapeutics Inc. Announces Release of X-Mini™ Cell Selection Kit for the CAR-T Research Market


Posted on: 03 Apr 18

RANCHO CORDOVA, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced the release of the X-Mini cell selection kit for the research market. The X-Mini isolates targeted cell subsets from blood and blood products, and is the first of several off-the-shelf kits that Cesca’s device subsidiary, ThermoGenesis, is developing for the research and development of CAR-T and other cell-based therapies.         

“The release of X-Mini represents a significant milestone for Cesca, as it signifies the initial launch of our proprietary CAR-TXpress platform,” said Chris Xu, chief executive officer of Cesca. “The X-Mini provides tangible advantages to research laboratories through a unique combination of attributes, including ease of use, high cell recovery and reproducibility, and minimal cost. During 2018, we look forward to the release of additional kits, including the X-Auto™ for non-commercial manufacturing of CAR-T cells as well as the X-Clini™, our first kit for Current Good Manufacturing Practice (cGMP)-compliant commercial manufacturing. The need for such products is strong, and we believe that our X-Series™ kits have the potential to revolutionize the rapidly evolving field of CAR-T therapy development and manufacturing.”      
     
The first X-Mini selection kit is designed for the isolation of CD3+ T cells from a starting population of peripheral blood mononuclear cells (PBMCs), but provides the flexibility to allow users to select any cell population for which they have a primary antibody.

About Cesca Therapeutics Inc.        
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress™ platform that addresses the critical unmet need for better cellular manufacturing and controls (CMC) for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.

Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
ir@cescatherapeutics.com 

Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
pschwartz@rxir.com 

GlobeNewswire
globenewswire.com

Last updated on: 03/04/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.